metricas
covid
Buscar en
Acta Otorrinolaringológica Española
Toda la web
Inicio Acta Otorrinolaringológica Española Prognostic capacity of PIV (pan-immune-inflammation value) in patients with head...
Journal Information
Vol. 75. Issue 2.
Pages 94-101 (March - April 2024)
Share
Share
Download PDF
More article options
Visits
11
Vol. 75. Issue 2.
Pages 94-101 (March - April 2024)
Original article
Prognostic capacity of PIV (pan-immune-inflammation value) in patients with head and neck squamous cell carcinoma
Capacidad pronóstica del PIV (pan-mmune-nflammation value) en pacientes con carcinoma escamoso de cabeza y cuello
Visits
11
Aina Sansaa, Cristina Valerob, Albert Pujolb, Blanca Sauterb, Julia Gayàb, Miquel Querb,c, Xavier Leónb,c,
Corresponding author
xleon@santpau.cat

Corresponding author.
a Servicio de Otorrinolaringología, Hospital Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, Spain
b Servicio de Otorrinolaringología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
c Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (4)
Table 1. Characteristics of the patients included in the study.
Table 2. Mean PIV value according to patient characteristics.
Table 3. Specific survival at 5 years according to category in the PIV value.
Table 4. Results of the multivariate analysis.
Show moreShow less
Additional material (1)
Abstract
Introduction

The pan-immune-inflammation value (PIV), an index that results from the following ratio: (neutrophils × monocytes × platelets)/lymphocytes, has been proposed as a prognostic biomarker in different tumour models. The aim of this study is to analyse the prognostic capacity of PIV in patients with head and neck squamous cell carcinoma (HNSCC).

Patients and methods

Retrospective study of 1187 patients with HNSCC treated at our centre between 2000−2017. PIV value was obtained from an analysis performed within 3 weeks prior to the start of treatment.

Results

PIV value was significantly associated with toxic consumption (0.001), tumour location (0.0001), tumour extension (0.0001), and histological grade (0.016). Four categories were defined based on PIV value using a recursive partitioning analysis: category I: PIV < 136.3 (n = 118, 9.9%), category II: PIV 136.3–451.1 (n = 594, 50.0%), category III: PIV 451.1−1,141.2 (n = 357, 30.1%), and category IV: PIV > 1141.2 (n = 118, 9.9%). A significant and ordered decrease in disease-specific survival was observed as the PIV category increased. This decrease in survival was independent of the type of treatment, tumour extension, or location of the primary tumour. The PIV category was and independent prognostic factor of disease-specific survival in a multivariable study.

Conclusions

PIV is a prognostic biomarker in patients with HNSCC.

Keywords:
Pan-immune-inflammation value (PIV)
Biomarker
Peripheral blood analysis
Head and neck squamous cell carcinoma
Resumen

Introducción El PIV (pan-immune-inflammation value), un índice que resulta del cociente (neutrófilos × monocitos × plaquetas) / linfocitos, ha sido propuesto como un biomarcador con capacidad pronóstica en diferentes modelos tumorales. El objetivo del presente estudio es analizar la capacidad pronóstica del PIV en pacientes con carcinoma escamoso de cabeza y cuello (CECC).

Pacientes y métodos Estudio retrospectivo de 1.187 pacientes con CECC tratados en nuestro centro durante el periodo 2000−2017. Se obtuvo el valor del PIV a partir de un análisis realizado en un intervalo inferior a las 3 semanas previas al inicio del tratamiento.

Resultados El valor del PIV se relacionó de forma significativa con el consumo de tóxicos (P = 0,001), la localización del tumour (0,0001), la extensión tumoral (0,0001), y el grado histológico (0,016). Mediante un análisis de partición recursiva se definieron cuatro categorías en función del valor del PIV: categoría I: PIV < 136,3 (n = 118, 9,9%), categoría II: PIV 136,3–451,1 (n = 594, 50,0%); categoría III: PIV 451,1–1.141,2 (n = 357, 30,1%); categoría IV: PIV > 1.141,2 (n = 118, 9,9%). Se pudo observar una reducción ordenada y significativa de la supervivencia específica a medida que se incrementaba la categoría en el valor del PIV. Esta disminución en la supervivencia se produjo de forma independiente al tipo de tratamiento, la extensión del tumour, o la localización del tumour primario. La categoría en el valor del PIV se relacionó de forma significativa con la supervivencia específica en un estudio multivariable.

Conclusiones El PIV es un biomarcador con capacidad pronóstica en los pacientes con CECC.

Palabras clave:
Pan-immune-inflammation value (PIV)
Biomarcador
Analítica sangre perifèrica
Carcinoma escamoso de cabeza y cuello

Article

These are the options to access the full texts of the publication Acta Otorrinolaringológica Española
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Acta Otorrinolaringológica Española

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos